The authors tested an EGFR inhibitor, afatinib, currently used in a clinical trial to treat GB (ClinicalTrials.gov, No.: NCT02423525), observing a drastic decrease of tumor cells in two out of three GB-like neoCORs, namely GBM-1 and GBM-3 [46]. This evidence concerns the gene EGFR and glioblastoma.